PMV Pharmaceuticals — Third Quarter 2026 Earnings Summary

PMV Pharmaceuticals reported a net loss of $34.4 million for the third quarter of 2026, driven largely by a $12.8 million non-cash loss from changes in the fair value of warrant liabilities associated with a recent public offering. The company announced the completion of enrollment for the primary analysis population in the Phase 2 monotherapy portion of its PYNNACLE clinical trial for rezatapopt in platinum-resistant ovarian cancer. Interim data from this trial showed an overall response rate of 46% among 76 patients, with a median duration of response of 10.0 months and a favorable safety profile. Following a $50 million public offering, PMV Pharma holds $108.5 million in cash and marketable securities, projecting a runway into the first quarter of 2028 to support the planned submission of a New Drug Application in early 2027.